RICHMOND, Va.--(BUSINESS WIRE)--Owens & Minor, Inc. (NYSE: OMI) today reported financial results for the second quarter ended June 30, 2025. In connection with a likely sale of the Company’s Products & Healthcare Services segment, the results herein, unless otherwise noted, reflect the Company’s continuing operations which primarily represent what was previously the Patient Direct segment and certain functional operations. “We are in the final stages of our robust process for the divest
Related Questions
How will the divestiture of the Products & Healthcare Services segment affect Owens & Minor's future revenue and profit margins?
What is the expected impact of the sale on the company's cash flow and balance sheet strength?
How does the performance of the continuing operations (Patient Direct segment) compare to the prior quarter and to analyst expectations?
Will Owens & Minor provide revised guidance or outlook for the remainder of 2025 following the divestiture?
What valuation multiples does the market currently assign to Owens & Minor, and how might they change post‑divestiture?
How might the divestiture influence Owens & Minor's competitive positioning within the medical distribution industry?
Are there any one‑time charges or gains associated with the sale that could distort the quarter's earnings?
What is the anticipated timeline for completing the divestiture, and what regulatory or closing hurdles remain?
How will the removal of the Products & Healthcare Services segment affect the company's segment reporting and segment margins?
What are the potential risks or upside scenarios for Owens & Minor's stock price in the next 3‑6 months based on this news release?